-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
CBD Combined With Essential Fatty Acids Is 40% More Efficient In Epilepsy Seizure Reduction Than Regular CBD, New Study
CBD Combined With Essential Fatty Acids Is 40% More Efficient In Epilepsy Seizure Reduction Than Regular CBD, New Study
CANAQUEST MEDICAL CORP (OTCPK:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system, announced statistically significant efficacy results from the clinical dose and efficacy study conducted by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure model. This result indicates that CQ-001 is stronger than standard CBD, and could be used a lower dose to achieve seizure control.
Highlights derived from the study are as follows:
-
The enhanced efficacy from these clinical studies further validates the pre-clinical trial results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University.
-
These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (phase II/III, double-blind trial, 60 patients).
-
CanaQuest has identified the regulatory pathways to obtain Rx drug identification numbers in Canada and the USA for epilepsy rare neurological conditions. CQ-001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years.
"Further testing will be necessary, however preliminary tests suggest that CQ-001 is stronger than regular CBD," stated Burnham, pharmacologist and co-director of EpLink.
Paul Ramsay, president, stated, "The clinical study results reconfirm the pre-clinical trial results conducted at Western University, and further substantiate the magnitude of this life-changing discovery."
Get your daily dose of cannabis news on Benzinga Cannabis. Don't miss out on any important developments in the industry.
Photo by Jeff W on Unsplash
CANAQUEST MEDICAL CORP (OTCPK:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system, announced statistically significant efficacy results from the clinical dose and efficacy study conducted by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure model. This result indicates that CQ-001 is stronger than standard CBD, and could be used a lower dose to achieve seizure control.
CANAQUEST醫療公司(OTCPK:CANQF)是一家臨床階段的生命科學公司,專注於中樞神經系統的下一代靶向大麻素療法的藥物發現和開發,該公司宣佈了由W·麥金太爾·伯納姆博士多倫多大學特梅蒂醫學院名譽教授。與標準CBD相比,CQ-001(大麻二酚“CBD”+IP配方--必需脂肪酸)癲癇發作減少40%在最大電休克驚厥模型中給予中等劑量。這一結果表明,CQ-001比標準CBD更強,可以使用較低的劑量來實現癲癇控制。
Highlights derived from the study are as follows:
這項研究的要點如下:
-
The enhanced efficacy from these clinical studies further validates the pre-clinical trial results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University.
-
These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (phase II/III, double-blind trial, 60 patients).
-
CanaQuest has identified the regulatory pathways to obtain Rx drug identification numbers in Canada and the USA for epilepsy rare neurological conditions. CQ-001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years.
-
這些臨床研究的增強療效進一步驗證了以下臨床前試驗結果史蒂文·拉維奧萊特博士他是西方大學的一名教授和神經學家。
-
這些結果為更小劑量的CBD產生預期結果而沒有負面副作用奠定了基礎,並將確定臨床試驗(II/III期,雙盲試驗,60名患者)的CQ-001劑量。
-
CanaQuest已經確定了在加拿大和美國用於癲癇罕見神經疾病的獲得Rx藥物識別號的調控途徑。CQ-001與其專有的加工和交付方法相結合,預計將在大約3年內獲得批准。
"Further testing will be necessary, however preliminary tests suggest that CQ-001 is stronger than regular CBD," stated Burnham, pharmacologist and co-director of EpLink.
董事的藥劑學家和聯合研究員伯納姆說:儘管初步測試表明CQ-001比普通的CBD更強,但進一步的測試是必要的。EPLink.
Paul Ramsay, president, stated, "The clinical study results reconfirm the pre-clinical trial results conducted at Western University, and further substantiate the magnitude of this life-changing discovery."
保羅·拉姆齊總裁說:“臨床研究結果再次證實了在西部大學進行的臨床前試驗結果,並進一步證實了這一改變人生的發現的重大意義。
Get your daily dose of cannabis news on Benzinga Cannabis. Don't miss out on any important developments in the industry.
獲取您的每日大麻用量新聞 在本辛加大麻上。不要錯過對該行業任何重要發展的期望。
Photo by Jeff W on Unsplash
不飛濺上Jeff W攝
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧